MD Anderson and BridgeBio Pharma Launch Navire Pharma to Develop Targeted Therapy for Patients with Difficult-to-Treat Cancer

HOUSTON and PALO ALTO, Calif., Oct. 4, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically-driven and treatment-resistant cancer. BridgeBio has committed $30 million and a team of senior business managers to the company, while MD Anderson, through its Institute […]

Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer

PALO ALTO, Calif., Sept. 28, 2017 /PRNewswire/ — Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced dosing of the first healthy adult cohort in the first-in-human, Phase 1 clinical trial of AG10 (NCT03294707). Eidos is developing AG10 as a targeted therapeutic for transthyretin (TTR) amyloidosis (ATTR). Eidos’ first clinical trial will evaluate AG10’s overall safety, tolerability and […]

Bridgebio Pharma Expands Investor Base, Raising an Additional $135 Million, and Discloses Genetic Disease Pipeline Programs

PALO ALTO, Calif., Sept. 13, 2017 /PRNewswire/ — BridgeBio Pharma, a clinical-stage biopharmaceutical company, today provided further detail on its growing pipeline of genetic disease assets and announced a new financing of $135 million, with potential to access significant additional capital via insiders. New investor Viking Global Investors and existing investor KKR co-led the round and were joined by existing […]

PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas and Third Closing of a $20 Million Series B Financing

MENLO PARK, Calif.–(BUSINESS WIRE)–PellePharm, a clinical-stage biopharmaceutical company committed to targeting hedgehog-driven disorders at the source, today announced topline data from its phase 2 trial evaluating the safety and efficacy of topical patidegib in patients with Gorlin Syndrome, a rare genetic disease that causes patients to develop multiple basal cell carcinomas (BCCs). PellePharm intends to […]

BridgeBio Pharma Launches Eidos Therapeutics to Develop Targeted Therapy for Fatal Heart Disease

PALO ALTO, Calif., April 27, 2017 /PRNewswire/ — BridgeBio Pharma today announced the launch of Eidos Therapeutics, a biopharmaceutical company developing a novel small-molecule treatment for transthyretin (TTR) amyloidosis. BridgeBio has committed $27 million and seasoned R&D executives to advance Eidos’ lead compound, AG10. “TTR amyloidosis is a progressive, fatal disease without an FDA-approved therapy. Patients and their families currently rely on […]

BridgeBio Pharma Launches with a Focus on Precision Medicines for Genetic Diseases

PALO ALTO, Calif.–(BUSINESS WIRE)–California-based BridgeBio Pharma has come out of stealth mode to reveal more detail about its novel approach to developing new therapies for genetic diseases. These diseases, often inherited and individually rare, collectively exact devastating effects on tens of millions of patients in the US alone, many of whom are children. The company, […]

PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

MENLO PARK, Calif.–(BUSINESS WIRE)–PellePharm, a clinical-stage biopharmaceutical company committed to developing patidegib, a topical hedgehog inhibitor to treat basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating orphan disease, announced its launch with financing from BridgeBio Pharma. This financing supports the development of topical patidegib through the completion of two phase 2 clinical […]